

B7-H3 (4Ig) /B7-H3b
Catalog # PVGS1808**Specification**

B7-H3 (4Ig) /B7-H3b - Product InformationPrimary Accession [Q5ZPR3-1](#)**Species**
Human**Sequence**
Gly27-Thr461**Purity**
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC**Endotoxin Level**
Less than 1EU per µg by the LAL method.**Biological Activity**
Immobilized B7-H3 (4Ig) /B7-H3b, His & Avi, Human (Cat.No.: Z03888) at 1.0 µg/ml (100 µl/Well) on the plate can bind Anti-B7-H3 Antibody, hFc Tag**Expression System**
HEK293**Theoretical Molecular Weight**
49.5 kDa**Formulation** **Lyophilized from a 0.22 µm filtered solution in PBS, pH 7.4.****Reconstitution**
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 µg/ml.**Storage & Stability**
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.**B7-H3 (4Ig) /B7-H3b - Additional Information****Target Background**
B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers. B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig-B7-H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.**B7-H3 (4Ig) /B7-H3b - Protein Information**

B7-H3 (4Ig) /B7-H3b - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

B7-H3 (4Ig) /B7-H3b - Images